Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

41. Combining smoking cessation interventions with LDCT lung cancer screening: A systematic review

Combining smoking cessation interventions with LDCT lung cancer screening: A systematic review Providing smoking cessation treatment with annual low dose CT (LDCT) screening offers an opportunity to reduce smoking-related morbidity and mortality. However, the optimal approach for delivering cessation interventions in the LDCT screening context is unknown. We searched for randomized controlled trials and observational studies with a control group testing a smoking cessation intervention among

2019 EvidenceUpdates

42. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab significantly improved progression-free survival and overall survival (OS) compared with platinum-based chemotherapy in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) with a programmed death ligand 1 tumor proportion

Full Text available with Trip Pro

2019 EvidenceUpdates

43. Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal)

Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) Dabr Dabrafenib with tr afenib with trametinib for treating ametinib for treating advanced metastatic BRAF V600E advanced metastatic BRAF V600E mutation-positiv mutation-positive non-small-cell lung e non-small-cell lung cancer (terminated appr cancer (terminated appraisal) aisal) T echnology appraisal guidance Published: 27 February 2019 nice.org.uk (...) /guidance/ta564 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Contents Contents Advice 3 Information 3 Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non- small-cell lung cancer (terminated appraisal) (TA564) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 3Advice Advice NICE is unable to make

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

44. Exercise training for advanced lung cancer. (PubMed)

Exercise training for advanced lung cancer. Patients with advanced lung cancer have a high symptom burden, which is often complicated by coexisting conditions. These issues, combined with the indirect effects of cancer treatment, can cumulatively lead patients to continued deconditioning and low exercise capacity. This is a concern as exercise capacity is considered a measure of whole body health, and is critical in a patient's ability to participate in life activities and tolerate difficult (...) treatments. There is evidence that exercise training improves exercise capacity and other outcomes, such as muscle force and health-related quality of life (HRQoL), in cancer survivors. However, the effectiveness of exercise training on these outcomes in people with advanced lung cancer is currently unclear.The primary aim of this review was to investigate the effects of exercise training on exercise capacity in adults with advanced lung cancer. Exercise capacity was defined as the six-minute walk

2019 Cochrane

45. Crizotinib (Alunbrig) - for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)

Crizotinib (Alunbrig) - for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization

2019 Health Canada - Drug and Health Product Register

46. Short-Term Readmissions After Open, Thoracoscopic, and Robotic Lobectomy for Lung Cancer Based on the Nationwide Readmissions Database

Short-Term Readmissions After Open, Thoracoscopic, and Robotic Lobectomy for Lung Cancer Based on the Nationwide Readmissions Database Readmission after surgery is an established surrogate indicator of quality of care. We aimed to compare short-term readmission rates and patient outcomes between open, video-assisted thoracoscopic (VATS), and robotic lobectomies in the Nationwide Readmissions Database (NRD).Adults who underwent open, VATS, or robotic lobectomy for lung cancer from 2010 to 2014 (...) were evaluated. Propensity-matched analysis was used to assess differences in readmission characteristics, GDP-adjusted cost, and mortality.Of the 129,539 lobectomies for lung cancer, 74,493 (57.5%) were open, 48,185 (37.2%) VATS, and 6861 (5.3%) robotic. Open surgery was associated with significantly higher readmission rate (10.5 vs 9.3%, p < 0.001), mortality (2 vs 1.2%, p < 0.001), index hospitalization cost [$21,846 (16,158-31,034) vs $20,779 (15,619-27,920), p < 0.001], and length of stay [6

2019 EvidenceUpdates

47. Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study

Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study The US guidelines recommend low-dose CT (LDCT) lung cancer screening for high-risk individuals. New solid nodules after baseline screening are common and have a high lung cancer probability. Currently, no evidence exists concerning the risk stratification of non-resolving new solid nodules at first LDCT screening after initial detection.In the Dutch-Belgian Randomized Lung Cancer Screening (NELSON) trial (...) nodules were resolving, leaving 356 (52%) participants with a non-resolving new solid nodule, of whom 25 (7%) were diagnosed with lung cancer. At first screening after initial detection, volume doubling time (VDT), volume, and VDT combined with a predefined ≥200 mm3 volume cut-off had high discrimination for lung cancer (VDT, area under the curve (AUC): 0.913; volume, AUC: 0.875; VDT and ≥200 mm3 combination, AUC: 0.939). Classifying a new solid nodule with either ≤590 days VDT or ≥200 mm3 volume

Full Text available with Trip Pro

2019 EvidenceUpdates

48. Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study

Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study Veliparib, a poly (ADP ribose) polymerase inhibitor, potentiated standard chemotherapy against small-cell lung cancer (SCLC) in preclinical studies. We evaluated the combination of veliparib with cisplatin and etoposide (CE; CE+V) doublet in untreated, extensive-stage SCLC (ES-SCLC).Patients with ES-SCLC, stratified by sex and serum

2019 EvidenceUpdates

49. Whole brain radiotherapy provides little benefit for lung cancer that has spread

Whole brain radiotherapy provides little benefit for lung cancer that has spread Whole brain radiotherapy provides little benefit for lung cancer that has spread Discover Portal Discover Portal Whole brain radiotherapy provides little benefit for lung cancer that has spread Published on 10 January 2017 doi: Radiotherapy to the whole brain makes little difference to people with the commonest type of lung cancer that has spread to the brain and cannot be operated on. This mainly UK-based trial (...) found no difference in overall survival and quality of life among people who had whole brain radiotherapy plus usual supportive care compared with people who received supportive care alone. This is the largest trial to assess the effect of this treatment in people with non-small cell lung cancer and multiple brain metastases (cancer deposits in the brain). Practice has been changing since early results of the trial were released. The final results reinforce the message that this treatment has little

2019 NIHR Dissemination Centre

50. Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer

Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer Discover Portal Discover Portal Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer Published on 28 February 2017 doi: Postoperative radiotherapy increases the risk of death by 18% for patients with non-small cell lung cancer that has been removed by surgery. Just (...) recurrence rates. Most of the trials are from over 30 years ago, so there is the possibility that newer radiotherapy techniques may be less harmful. Nevertheless, this review provides the best evidence to date that postoperative radiotherapy may not be appropriate as a routine treatment for non-small cell lung cancer. Share your views on the research. Why was this study needed? Lung cancer is the second most common cancer in the UK with 37,453 new cases registered in 2014. The majority of lung cancers

2019 NIHR Dissemination Centre

51. Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: nested case-control study within Lung Cancer Cohort Consortium. (PubMed)

Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: nested case-control study within Lung Cancer Cohort Consortium. To conduct a comprehensive analysis of prospectively measured circulating high sensitivity C reactive protein (hsCRP) concentration and risk of lung cancer overall, by smoking status (never, former, and current smokers), and histological sub-type.Nested case-control study.20 population based cohort studies in Asia, Europe, Australia (...) , and the United States.5299 patients with incident lung cancer, with individually incidence density matched controls.Circulating hsCRP concentrations in prediagnostic serum or plasma samples.Incident lung cancer diagnosis.A positive association between circulating hsCRP concentration and the risk of lung cancer for current (odds ratio associated with a doubling in hsCRP concentration 1.09, 95% confidence interval 1.05 to 1.13) and former smokers (1.09, 1.04 to 1.14) was observed, but not for never smokers (P

Full Text available with Trip Pro

2019 BMJ

52. A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer

A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer Stereotactic body radiation therapy is the preferred treatment modality for patients with inoperable early-stage non-small cell lung cancer. However, comparative outcomes between stereotactic body radiation therapy and surgery for high-risk patients remain controversial. The primary aim of the present meta-analysis was to assess overall survival in matched (...) and unmatched patient cohorts undergoing stereotactic body radiation therapy or surgery. Secondary end points included cancer-specific survival, disease-free survival, disease recurrence, and perioperative outcomes.A systematic review of relevant studies was performed through online databases using predefined criteria. The most updated studies were selected for meta-analysis according to unmatched and matched patient cohorts.Thirty-two studies were identified in the systematic review, and 23 were selected

2019 EvidenceUpdates

53. Impact of breathing exercises in subjects with lung cancer undergoing surgical resection: A systematic review and meta-analysis

Impact of breathing exercises in subjects with lung cancer undergoing surgical resection: A systematic review and meta-analysis To assess the effects of breathing exercises on postoperative pulmonary complications (PPCs), pulmonary function, 6-min walk distance (6MWD) and the length of hospital stay (LOS) in lung cancer patients undergoing lung surgery.Lung cancer patients undergoing lung resection have poor pulmonary function and multiple PPCs. Breathing exercises may improve (...) exercises could improve lung function, decrease the incidence of PPCs and LOS in a sample of lung cancer patients undergoing pulmonary surgery.The analysis suggests that breathing exercises should be considered as a respiratory rehabilitation programme for lung cancer patients undergoing lung surgery in clinical practice.© 2018 John Wiley & Sons Ltd.

2019 EvidenceUpdates

54. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. (PubMed)

Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. Anlotinib is an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor, and stem cell factor receptor (c-Kit). In the phase III ALTER-0303 trial (Clinical Trial Registry ID: NCT 02388919), anlotinib significantly improved overall survival versus placebo in advanced (...) non-small cell lung cancer patients who had received at least two previous chemotherapy and epidermal growth factor receptor/anaplastic lymphoma kinase targeted therapy regimens. This study summarized adverse event management in this trial.Patients were randomized (2:1) to anlotinib or placebo up to progression or intolerable toxicity. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 and managed by investigators. Key

Full Text available with Trip Pro

2019 Thoracic cancer

55. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic non-small cell lung cancer

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic non-small cell lung cancer SPECIAL ARTICLE Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS Y.-L. Wu 1 * , D. Planchard 2 ,S.Lu 3 , H. Sun 4 , N. Yamamoto 5 , D.-W. Kim 6 , D. S. W. Tan 7 , J. C.-H. Yang 8 , M. Azrif 9 , T. Mitsudomi 10 , K. Park 11 , R. A. Soo (...) 12 , J. W. C. Chang 13 , A. Alip 14 , S. Peters 15 & J.-Y. Douillard 16 1 Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, P.R. China; 2 Department of Medical Oncology, Thoracic Group, Gustave Roussy, Villejuif, France; 3 Shanghai Chest Hospital, Shanghai; 4 Guangdong Lung Cancer Institute, Guangdong Lung Cancer Institute, Guangdong General Hospital, School of Medicine, South China University of Technology, Guangzhou, P.R. China; 5

2019 European Society for Medical Oncology

56. ASTRO Guideline on Palliative Radiation Therapy for Non-small Cell Lung Cancer (NSCLC) - Update

ASTRO Guideline on Palliative Radiation Therapy for Non-small Cell Lung Cancer (NSCLC) - Update Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline - Practical Radiation Oncology Email/Username: Password: Remember me Search Terms Search within Search Share this page: Volume 8, Issue 4, Pages 245–250 Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update (...) Accepted: February 19, 2018 ; Received: February 6, 2018 ; Abstract Purpose To revise the recommendation on the use of concurrent chemotherapy (CC) with palliative thoracic external beam radiation therapy (EBRT) made in the original 2011 American Society for Radiation Oncology guideline on palliative thoracic radiation for lung cancer. Methods and materials Based on a systematic PubMed search showing new evidence for this key question, the task force felt an update was merited. Guideline

2019 American Society for Radiation Oncology

57. The value of Lunx-mRNA positive expression and clinicopathology in non-small cell lung cancer: a meta-analysis

The value of Lunx-mRNA positive expression and clinicopathology in non-small cell lung cancer: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

58. The association between quality of life and unmet supportive care needs in patients with lung cancer and their carers

The association between quality of life and unmet supportive care needs in patients with lung cancer and their carers Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

59. The optimal treatment for non-small cell lung cancer with brain metastasis: a network meta-analysis

The optimal treatment for non-small cell lung cancer with brain metastasis: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

60. The optimal treatment for metastatic non-small cell lung cancer without brain metastasis: a network meta-analysis

The optimal treatment for metastatic non-small cell lung cancer without brain metastasis: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO